Nilay D Shah

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10682772/publications.pdf

Version: 2024-02-01

24511 27035 114 14,089 166 58 citations h-index g-index papers 168 168 168 19081 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Clinical studies sponsored by digital health companies participating in the FDA's Precertification Pilot Program: A cross-sectional analysis. Clinical Trials, 2022, 19, 119-122.	0.7	2
2	Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019. JAMA Internal Medicine, 2022, 182, 185.	2.6	16
3	Association of Area-Level Socioeconomic Deprivation With Hypoglycemic and Hyperglycemic Crises in US Adults With Diabetes. JAMA Network Open, 2022, 5, e2143597.	2.8	24
4	Use of Mechanical Circulatory Support Devices Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. JAMA Network Open, 2021, 4, e2037748.	2.8	54
5	Association of outpatient ACE inhibitors and angiotensin receptor blockers and outcomes of acute respiratory illness: a retrospective cohort study. BMJ Open, 2021, 11, e044010.	0.8	5
6	The Impact of Antifungal Prophylaxis in Lung Transplant Recipients. Annals of the American Thoracic Society, 2021, 18, 468-476.	1.5	10
7	Increasing risk-concordant cardiovascular care in diverse health systems: a mixed methods pragmatic stepped wedge cluster randomized implementation trial of shared decision making (SDM4IP). Implementation Science Communications, 2021, 2, 43.	0.8	4
8	Use of Post–Acute Care Services and Readmissions After Acute Myocardial Infarction Complicated by Cardiac Arrest and Cardiogenic Shock. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 320-329.	1.2	11
9	Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 286-297.	1.2	3
10	Artificial intelligence–enabled electrocardiograms for identification of patients with low ejection fraction: a pragmatic, randomized clinical trial. Nature Medicine, 2021, 27, 815-819.	15.2	154
11	Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019. JAMA Network Open, 2021, 4, e2113224.	2.8	19
12	Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications. BMC Pulmonary Medicine, 2021, 21, 239.	0.8	6
13	Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2021, 18, 1121-1128.	1.5	37
14	Sociodemographic, Clinical, and Treatment-Related Factors Associated With Hyperglycemic Crises Among Adults With Type 1 or Type 2 Diabetes in the US From 2014 to 2020. JAMA Network Open, 2021, 4, e2123471.	2.8	22
15	Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment. JAMA Network Open, 2021, 4, e2130587.	2.8	28
16	Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval. JAMA Network Open, 2021, 4, e2133667.	2.8	16
17	Association Between Area-Level Socioeconomic Deprivation and Diabetes Care Quality in US Primary Care Practices. JAMA Network Open, 2021, 4, e2138438.	2.8	34
18	Risk of Gastrointestinal Bleeding Increases With Combinations of Antithrombotic Agents and Patient Age. Clinical Gastroenterology and Hepatology, 2020, 18, 337-346.e19.	2.4	30

#	Article	IF	Citations
19	Comparative Effectiveness of Sacubitril-ValsartanÂVersus ACE/ARB Therapy in Heart Failure With ReducedÂEjection Fraction. JACC: Heart Failure, 2020, 8, 43-54.	1.9	40
20	Use of Potentially Nephrotoxic Medications by U.S. Adults with Chronic Kidney Disease: NHANES, 2011–2016. Journal of General Internal Medicine, 2020, 35, 1092-1101.	1.3	6
21	What is the effect of a decision aid in potentially vulnerable parents? Insights from the head CT choice randomized trial. Health Expectations, 2020, 23, 63-74.	1.1	7
22	Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients With Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006515.	0.9	20
23	Long-Term Outcomes of Acute Myocardial Infarction With Concomitant Cardiogenic Shock and Cardiac Arrest. American Journal of Cardiology, 2020, 133, 15-22.	0.7	22
24	Assessment of Trends in Statin Therapy for Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults From 2007 to 2016. JAMA Network Open, 2020, 3, e2025505.	2.8	63
25	Development and evaluation of a patient-centered quality indicator for the appropriateness of type 2 diabetes management. BMJ Open Diabetes Research and Care, 2020, 8, e001878.	1.2	4
26	Development and Validation of a Risk Stratification Model Using Disease Severity Hierarchy for Mortality or Major Cardiovascular Event. JAMA Network Open, 2020, 3, e208270.	2.8	8
27	Capacity Coaching: A Focused Ethnographic Evaluation in Clinical Practice. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2020, 4, 190-202.	1.2	5
28	Association of Neighborhood Measures of Social Determinants of Health With Breast, Cervical, and Colorectal Cancer Screening Rates in the US Midwest. JAMA Network Open, 2020, 3, e200618.	2.8	140
29	Generalizability of the CASTLE-AF trial: Catheter ablation for patients with atrial fibrillation and heart failure in routine practice. Heart Rhythm, 2020, 17, 1057-1065.	0.3	54
30	Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. JAMA - Journal of the American Medical Association, 2020, 323, 734.	3.8	260
31	Association of Cumulative Multimorbidity, Glycemic Control, and Medication Use With Hypoglycemia-Related Emergency Department Visits and Hospitalizations Among Adults With Diabetes. JAMA Network Open, 2020, 3, e1919099.	2.8	65
32	Commentary on Bertagnolli et al.: Leveraging electronic health record data for clinical trials—a brave new world. Clinical Trials, 2020, 17, 243-246.	0.7	2
33	Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017. JAMA Network Open, 2020, 3, e203284.	2.8	58
34	Paradox of glycemic management: multimorbidity, glycemic control, and high-risk medication use among adults with diabetes. BMJ Open Diabetes Research and Care, 2020, 8, e001007.	1.2	29
35	Catheter-related complications and mortality of atrial fibrillation ablation following introduction of contact force-sensing technology. BMJ Surgery, Interventions, and Health Technologies, 2020, 2, e000058.	0.6	2
36	Adoption of New Glucose-Lowering Medications in the U.S.â€"The Case of SGLT2 Inhibitors: Nationwide Cohort Study. Diabetes Technology and Therapeutics, 2019, 21, 702-712.	2.4	82

#	Article	IF	CITATIONS
37	Feasibility of Using Real-World Data to Replicate Clinical Trial Evidence. JAMA Network Open, 2019, 2, e1912869.	2.8	167
38	Racial and Ethnic Differences in 30-Day Hospital Readmissions Among US Adults With Diabetes. JAMA Network Open, 2019, 2, e1913249.	2.8	38
39	Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 168-174.	2.5	102
40	Atrial fibrillation ablation in practice: assessing CABANA generalizability. European Heart Journal, 2019, 40, 1257-1264.	1.0	105
41	Response by Siontis et al to Letter Regarding Article, "Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States― Circulation, 2019, 139, 1563-1564.	1.6	0
42	Prospective validation of a deep learning electrocardiogram algorithm for the detection of left ventricular systolic dysfunction. Journal of Cardiovascular Electrophysiology, 2019, 30, 668-674.	0.8	98
43	Older Drugs With Limited Trial Evidence: Are They Worth the Expense?. Annals of Internal Medicine, 2019, 171, 602.	2.0	3
44	Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings. Journal of Managed Care & Decialty Pharmacy, 2019, 25, 1201-1217.	0.5	0
45	Generic Drugs in the United States: Policies to Address Pricing and Competition. Clinical Pharmacology and Therapeutics, 2019, 105, 329-337.	2.3	27
46	Older Drugs With Limited Trial Evidence: Are They Worth the Expense? The Case of Repository Corticotropin Marketed as H.P. Acthar Gel. Annals of Internal Medicine, 2019, 170, 791.	2.0	9
47	National trends in emergency department visits and hospitalizations for foodâ€induced anaphylaxis in <scp>US</scp> children. Pediatric Allergy and Immunology, 2018, 29, 538-544.	1.1	85
48	Comparative Assessment of Patient Preferences and Tolerability in Barrett Esophagus Screening. Journal of Clinical Gastroenterology, 2018, 52, 880-884.	1.1	6
49	Recurrent hospitalizations for severe hypoglycemia and hyperglycemia among U.S. adults with diabetes. Journal of Diabetes and Its Complications, 2018, 32, 693-701.	1.2	25
50	Costs associated with Barrett's esophagus screening in the community: an economic analysis of a prospective randomized controlled trial of sedated versus hospital unsedated versus mobile community unsedated endoscopy. Gastrointestinal Endoscopy, 2018, 87, 88-94.e2.	0.5	35
51	Effectiveness of a Decision Aid in Potentially Vulnerable Patients: A Secondary Analysis of the Chest Pain Choice Multicenter Randomized Trial. Medical Decision Making, 2018, 38, 69-78.	1.2	8
52	Impact of a Shared Decision Making Intervention on Health Care Utilization: A Secondary Analysis of the Chest Pain Choice Multicenter Randomized Trial. Academic Emergency Medicine, 2018, 25, 293-300.	0.8	10
53	New and incremental FDA black box warnings from 2008 to 2015. Expert Opinion on Drug Safety, 2018, 17, 117-123.	1.0	21
54	Effect of the Head Computed Tomography Choice Decision Aid in Parents of Children With Minor Head Trauma. JAMA Network Open, 2018, 1, e182430.	2.8	48

#	Article	IF	Citations
55	Association of Surgical Left Atrial Appendage Occlusion With Subsequent Stroke and Mortality Among Patients Undergoing Cardiac Surgery. JAMA - Journal of the American Medical Association, 2018, 319, 2116.	3.8	114
56	Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation, 2018, 138, 1519-1529.	1.6	359
57	Access to primary care and computed tomography use in the emergency department. BMC Health Services Research, 2018, 18, 154.	0.9	31
58	The Learning Healthcare System and Cardiovascular Care: A Scientific Statement From the American Heart Association. Circulation, 2017, 135, e826-e857.	1.6	87
59	Observation Status or Inpatient Admission: Impact of Patient Disposition on Outcomes and Utilization Among Emergency Department Patients With Chest Pain. Academic Emergency Medicine, 2017, 24, 152-160.	0.8	9
60	Influence of Direct Oral Anticoagulants onÂRates of Oral Anticoagulation for AtrialÂFibrillation. Journal of the American College of Cardiology, 2017, 69, 2475-2484.	1.2	220
61	Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010. JAMA - Journal of the American Medical Association, 2017, 317, 1854.	3.8	235
62	Non–Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. Journal of the American College of Cardiology, 2017, 69, 2779-2790.	1.2	398
63	Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study. Gastroenterology, 2017, 152, 1014-1022.e1.	0.6	166
64	Feeding Tubes and Health Care Service Utilization in Amyotrophic Lateral Sclerosis: Benefits and Limits to a Retrospective, Multicenter Study Using Big Data. Inquiry (United States), 2017, 54, 004695801773242.	0.5	0
65	Long-term stroke and bleeding risk in patients with atrial fibrillation treated with oral anticoagulants in contemporary practice: Providing evidence for shared decision-making. International Journal of Cardiology, 2017, 245, 174-177.	0.8	8
66	National utilization of regional lymph node dissection among patients with kidney cancer and clinical lymphadenopathy undergoing radical nephrectomy. Cancer Treatment and Research Communications, 2017, 12, 14-18.	0.7	0
67	Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2017, 70, 2621-2632.	1.2	198
68	Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013. Diabetes Care, 2017, 40, 468-475.	4.3	249
69	Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ: British Medical Journal, 2017, 357, j1680.	2.4	93
70	Measurement with a wink. BMJ Quality and Safety, 2017, 26, 849-851.	1.8	15
71	Reply. Journal of the American College of Cardiology, 2017, 70, 2734-2735.	1.2	3
72	Increased Computed Tomography Utilization in the Emergency Department and Its Association with Hospital Admission. Western Journal of Emergency Medicine, 2017, 18, 835-845.	0.6	96

#	Article	IF	Citations
73	Shared decision making for stroke prevention in atrial fibrillation: study protocol for a randomized controlled trial. Trials, 2017, 18, 443.	0.7	24
74	Comparative Trends and Downstream Outcomes of Coronary Computed Tomography Angiography and Cardiac Stress Testing in Emergency Department Patients With Chest Pain: An Administrative Claims Analysis. Academic Emergency Medicine, 2016, 23, 1022-1030.	0.8	11
75	Incidence and Early Outcomes of Heart Failure in Commercially Insured and Medicare Advantage Patients, 2006 to 2014. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 332-337.	0.9	14
76	Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. Chest, 2016, 150, 1302-1312.	0.4	210
77	Inclusion of Hypoglycemia in Clinical Practice Guidelines and Performance Measures in the Care of Patients With Diabetes. JAMA Internal Medicine, 2016, 176, 1714.	2.6	25
78	PCI Choice Decision Aid for Stable Coronary Artery Disease. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 767-776.	0.9	56
79	Shared decision making in patients with low risk chest pain: prospective randomized pragmatic trial. BMJ, The, 2016, 355, i6165.	3.0	106
80	Intensive Treatment and Severe Hypoglycemia Among Adults With Type 2 Diabetes. JAMA Internal Medicine, 2016, 176, 969.	2.6	115
81	Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvals. Trials, 2016, 17, 199.	0.7	66
82	Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. Journal of the American Heart Association, $2016, 5, .$	1.6	334
83	Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. Journal of the American Heart Association, 2016, 5, .	1.6	341
84	Reply to Idelevich and Beck. Clinical Infectious Diseases, 2016, 62, 269-270.	2.9	2
85	Encounter Decision Aid vs. Clinical Decision Support or Usual Care to Support Patient-Centered Treatment Decisions in Osteoporosis: The Osteoporosis Choice Randomized Trial II. PLoS ONE, 2015, 10, e0128063.	1.1	58
86	Effect of Multiple Chronic Diseases on Health Care Expenditures in Childhood. Journal of Primary Care and Community Health, 2015, 6, 2-9.	1.0	26
87	HbA $<$ sub $>$ 1c $<$ /sub $>$ 0vertesting and overtreatment among US adults with controlled type 2 diabetes, 2001-13: observational population based study. BMJ, The, 2015, 351, h6138.	3.0	45
88	A Randomized Comparative Effectiveness Trial of Novel Endoscopic Techniques and Approaches for Barrett's Esophagus Screening in the Community. American Journal of Gastroenterology, 2015, 110, 148-158.	0.2	92
89	Risk of stroke after catheter ablation versus cardioversion for atrial fibrillation: A propensity-matched study of 24,244 patients. Heart Rhythm, 2015, 12, 1154-1161.	0.3	51
90	Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ, The, 2015, 350, h1857-h1857.	3.0	291

#	Article	IF	Citations
91	Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control. JAMA Internal Medicine, 2015, 175, 356.	2.6	317
92	Shared Decision Making for Antidepressants in Primary Care. JAMA Internal Medicine, 2015, 175, 1761.	2.6	107
93	Use of Post-acute Care Services and Readmissions After LeftÂVentricular Assist Device Implantation in Privately InsuredÂPatients. Journal of Cardiac Failure, 2015, 21, 816-823.	0.7	23
94	Accuracy of annual prescription drug expenditure forecasts in <i>AJHP</i> . American Journal of Health-System Pharmacy, 2015, 72, 1642-1648.	0.5	3
95	Randomized Trial of Rapid Multiplex Polymerase Chain Reaction–Based Blood Culture Identification and Susceptibility Testing. Clinical Infectious Diseases, 2015, 61, 1071-1080.	2.9	385
96	Trends and predictors of readmission after catheter ablation for atrial fibrillation, 2009-2013. American Heart Journal, 2015, 170, 483-489.	1.2	21
97	Changing trends in type 2 diabetes mellitus treatment intensification, 2002-2010. American Journal of Managed Care, 2015, 21, e288-96.	0.8	12
98	Response to Comments on Zhang et al. Second-Line Agents for Glycemic Control for Type 2 Diabetes: Are Newer Agents Better? Diabetes Care 2014;37:1338–1345. Diabetes Care, 2014, 37, e206-e207.	4.3	0
99	Implementation of Shared Decision Making in Cardiovascular Care. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 797-803.	0.9	47
100	Use and Out-of-Pocket Costs of Insulin for Type 2 Diabetes Mellitus From 2000 Through 2010. JAMA - Journal of the American Medical Association, 2014, 311, 2331.	3.8	75
101	Out of Context. Medical Care, 2014, 52, S92-S100.	1.1	96
102	Optum Labs: Building A Novel Node In The Learning Health Care System. Health Affairs, 2014, 33, 1187-1194.	2.5	338
103	Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012. JAMA - Journal of the American Medical Association, 2014, 311, 368.	3.8	327
104	Trends in Computed Tomography Utilization Rates. Journal of Patient Safety, 2014, 10, 52-58.	0.7	78
105	Second-Line Agents for Glycemic Control for Type 2 Diabetes: Are Newer Agents Better?. Diabetes Care, 2014, 37, 1338-1345.	4.3	57
106	Multiple Chronic Conditions and Asthma: Implications for Practice and Research. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 518-524.	2.0	7
107	Effectiveness of the head CT choice decision aid in parents of children with minor head trauma: study protocol for a multicenter randomized trial. Trials, 2014, 15, 253.	0.7	37
108	Effectiveness of the Chest Pain Choice decision aid in emergency department patients with low-risk chest pain: study protocol for a multicenter randomized trial. Trials, 2014, 15, 166.	0.7	22

#	Article	IF	Citations
109	Off-hour presentation and outcomes in patients with acute ischemic stroke: A systematic review and meta-analysis. European Journal of Internal Medicine, 2014, 25, 394-400.	1.0	55
110	Translating comparative effectiveness of depression medications into practice by comparing the depression medication choice decision aid to usual care: study protocol for a randomized controlled trial. Trials, 2013, 14, 127.	0.7	21
111	Determinants of fluoroscopy time for invasive coronary angiography and percutaneous coronary intervention: Insights from the NCDR $<$ sup $>$ Â $^{@}<$ /sup $>$. Catheterization and Cardiovascular Interventions, 2013, 82, 1091-1105.	0.7	29
112	Shared decision making for patients with type 2 diabetes: a randomized trial in primary care. BMC Health Services Research, 2013, 13, 301.	0.9	95
113	Is patient assessment of asthma care delivery associated with publicly reported performance measures?. Journal of Asthma, 2013, 50, 908-914.	0.9	2
114	Outcomes and total costs of outpatient vs. inpatient peri-procedural anticoagulation management of mechanical prosthetic heart valve patients. International Journal of Cardiology, 2013, 168, 5311-5315.	0.8	8
115	â€They leave at least believing they had a part in the discussion': Understanding decision aid use and patient–clinician decision-making through qualitative research. Patient Education and Counseling, 2013, 93, 86-94.	1.0	42
116	Shared decision-making and comparative effectiveness research for patients with chronic conditions: an urgent synergy for better health. Journal of Comparative Effectiveness Research, 2013, 2, 595-603.	0.6	19
117	Dissemination and implementation of comparative effectiveness evidence: key informant interviews with Clinical and Translational Science Award institutions. Journal of Comparative Effectiveness Research, 2013, 2, 185-194.	0.6	23
118	Populationâ€based trends in urinary diversion among patients undergoing radical cystectomy for bladder cancer. BJU International, 2013, 112, 478-484.	1.3	54
119	Self-Report of Hypoglycemia and Health-Related Quality of Life in Patients with Type 1 and Type 2 Diabetes. Endocrine Practice, 2013, 19, 792-799.	1.1	54
120	Episode-Based Payment: Evaluating the Impact on Chronic Conditions. Medicare & Medicaid Research Review, 2013, 3, E1-E26.	1.3	17
121	Risk-stratification methods for identifying patients for care coordination. American Journal of Managed Care, 2013, 19, 725-32.	0.8	73
122	A Randomized Controlled Trial of Telemonitoring in Older Adults With Multiple Health Issues to Prevent Hospitalizations and Emergency Department Visits. Archives of Internal Medicine, 2012, 172, 773-9.	4.3	178
123	Optimization of PSA Screening Policies. Medical Decision Making, 2012, 32, 337-349.	1.2	41
124	Increased Mortality of Patients With Diabetes Reporting Severe Hypoglycemia. Diabetes Care, 2012, 35, 1897-1901.	4.3	458
125	Optimization of Prostate Biopsy Referral Decisions. Manufacturing and Service Operations Management, 2012, 14, 529-547.	2.3	72
126	Projecting future drug expendituresâ€"2012. American Journal of Health-System Pharmacy, 2012, 69, 405-421.	0.5	59

#	Article	lF	Citations
127	The Chest Pain Choice Decision Aid. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 251-259.	0.9	226
128	Optimizing Statin Treatment Decisions for Diabetes Patients in the Presence of Uncertain Future Adherence. Medical Decision Making, 2012, 32, 154-166.	1.2	37
129	State Medicaid Programs Did Not Make Use Of Prior Authorization To Promote Safer Prescribing After Rosiglitazone Warning. Health Affairs, 2012, 31, 188-198.	2.5	13
130	Generic Atorvastatin and Health Care Costs. New England Journal of Medicine, 2012, 366, 201-204.	13.9	56
131	The Effects of Incremental Costs of Smoking and Obesity on Health Care Costs Among Adults. Journal of Occupational and Environmental Medicine, 2012, 54, 286-291.	0.9	49
132	The Implications of Hospital Acquired Adverse Events on Mortality, Length of Stay and Costs for Patients Undergoing Radical Cystectomy for Bladder Cancer. Journal of Urology, 2012, 187, 2011-2017.	0.2	88
133	The impact of decision aids to enhance shared decision making for diabetes (the DAD study): protocol of a cluster randomized trial. BMC Health Services Research, 2012, 12, 130.	0.9	25
134	Care management for Type 2 diabetes in the United States: a systematic review and meta-analysis. BMC Health Services Research, 2012, 12, 72.	0.9	51
135	Cumulative complexity: a functional, patient-centered model of patient complexity can improve research and practice. Journal of Clinical Epidemiology, 2012, 65, 1041-1051.	2.4	479
136	Regulatory Review of Novel Therapeutics â€" Comparison of Three Regulatory Agencies. New England Journal of Medicine, 2012, 366, 2284-2293.	13.9	146
137	Contemporary trends of inâ€hospital complications and mortality for radical cystectomy. BJU International, 2012, 110, 1163-1168.	1.3	59
138	Use of a Decision Aid to Improve Treatment Decisions in Osteoporosis: The Osteoporosis Choice Randomized Trial. American Journal of Medicine, 2011, 124, 549-556.	0.6	167
139	Individuals with diabetes preferred that future trials use patient-important outcomes and provide pragmatic inferences. Journal of Clinical Epidemiology, 2011, 64, 743-748.	2.4	54
140	Why Do Women Reject Bisphosphonates for Osteoporosis? A Videographic Study. PLoS ONE, 2011, 6, e18468.	1.1	22
141	Differences in demographic composition and in work, social, and functional limitations among the populations with unipolar depression and bipolar disorder: results from a nationally representative sample. Health and Quality of Life Outcomes, 2011, 9, 90.	1.0	46
142	What have we learnt from the rosiglitazone saga?. BMJ: British Medical Journal, 2011, 342, d1354-d1354.	2.4	9
143	Lifetime Costs of Medical Care After Heart Failure Diagnosis. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 68-75.	0.9	216
144	Personalizing Evidence-Based Primary Prevention With Aspirin. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 260-262.	0.9	7

#	Article	IF	Citations
145	The structure of optimal statin initiation policies for patients with Type 2 diabetes. IIE Transactions on Healthcare Systems Engineering, 2011, 1, 49-65.	0.8	33
146	Projecting future drug expenditures—2011. American Journal of Health-System Pharmacy, 2011, 68, 921-932.	0.5	34
147	The role of the electronic medical record in the assessment of health related quality of life. AMIA Annual Symposium proceedings, 2011, 2011, 1080-8.	0.2	4
148	Effect of multiple chronic conditions among working-age adults. American Journal of Managed Care, 2011, 17, 118-22.	0.8	57
149	Translating Comparative Effectiveness Into Practice. Medical Care, 2010, 48, S153-S158.	1.1	47
150	The Chest Pain Choice trial: a pilot randomized trial of a decision aid for patients with chest pain in the emergency department. Trials, 2010, 11, 57.	0.7	25
151	Projecting future drug expenditures—2010. American Journal of Health-System Pharmacy, 2010, 67, 919-928.	0.5	19
152	Responding to an FDA Warning — Geographic Variation in the Use of Rosiglitazone. New England Journal of Medicine, 2010, 363, 2081-2084.	13.9	71
153	Cumulative Exposure to Ionizing Radiation From Diagnostic and Therapeutic Cardiac Imaging Procedures. Journal of the American College of Cardiology, 2010, 56, 702-711.	1.2	166
154	Effect of Weekend Hospital Admission on Gastrointestinal Hemorrhage Outcomes. Digestive Diseases and Sciences, 2010, 55, 1658-1666.	1.1	81
155	Optimizing the Start Time of Statin Therapy for Patients with Diabetes. Medical Decision Making, 2009, 29, 351-367.	1.2	71
156	Projecting future drug expenditures—2009. American Journal of Health-System Pharmacy, 2009, 66, 237-257.	0.5	36
157	The Diabetes Mellitus Medication Choice Decision Aid. Archives of Internal Medicine, 2009, 169, 1560-8.	4.3	247
158	Protocol for the Osteoporosis Choice trial. A pilot randomized trial of a decision aid in primary care practice. Trials, 2009, 10, 113.	0.7	30
159	Long-term Medication Adherence after Myocardial Infarction: Experience of a Community. American Journal of Medicine, 2009, 122, 961.e7-961.e13.	0.6	139
160	Hospitalizations After Heart Failure Diagnosis. Journal of the American College of Cardiology, 2009, 54, 1695-1702.	1.2	410
161	Exposure to Low-Dose Ionizing Radiation from Medical Imaging Procedures. New England Journal of Medicine, 2009, 361, 849-857.	13.9	1,175
162	Chronic Care Model and Shared Care in Diabetes: Randomized Trial of an Electronic Decision Support System. Mayo Clinic Proceedings, 2008, 83, 747-757.	1.4	98

#	ARTICLE	IF	CITATION
163	Projecting future drug expenditures—2006. American Journal of Health-System Pharmacy, 2006, 63, 123-138.	0.5	26
164	Projecting future drug expenditures—2003. American Journal of Health-System Pharmacy, 2003, 60, 137-149.	0.5	25
165	Projecting future drug expenditures—2002. American Journal of Health-System Pharmacy, 2002, 59, 131-142.	0.5	13
166	Shared Decision-Making for Patients Hospitalized with Acute Myocardial Infarction: A Randomized Trial. Patient Preference and Adherence, 0, Volume 16, 1395-1404.	0.8	1